Challenges With Triplet Regimens for the Treatment of Hematologic Malignancies
Alan Skarbnik, MD, director of the Chronic Lymphocytic Leukemia Program at John Theurer Cancer Center, discusses the possibility of triplet combinations for the treatment of hematologic malignances. The biggest challenge with this type of treatment regimen is the increased risk of adverse events.
Alan Skarbnik, MD, director of the Chronic Lymphocytic Leukemia Program at John Theurer Cancer Center, discusses the possibility of triplet combinations for the treatment of hematologic malignances. The biggest challenge with this type of treatment regimen is the increased risk of adverse events (AEs).
Adding a new drug to any combination can be tricky due to the potential increase in AEs with these regimens. For example, the combination of ipilimumab (Yervoy) and a PD-1 inhibitor increases toxicity, which would only increase more when adding a third drug. However, Skarbnik says that is the cost to pay for the efficacy that has been found with this particular combination.
FDA Greenlights Treosulfan/Fludarabine Combo for AlloHSCT in AML and MDS
January 24th 2025The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia or myelodysplastic syndromes has been approved by the FDA.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
